Drug Type Monoclonal antibody |
Synonyms U3 1565, U3-1565 |
Target |
Action inhibitors |
Mechanism HBEGF inhibitors(Heparin-binding EGF-like growth factor inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 1 | United States | 01 Jan 2011 | |
Ovarian Cancer | Phase 1 | United States | 01 Jan 2011 | |
Colorectal Cancer | Phase 1 | Japan | - | |
Colorectal Cancer | Phase 1 | - | - | |
Colorectal Cancer | Phase 1 | - | - |
Phase 1 | 22 | oiqrvaegtx(lwqqvnohcx) = zytccnlpzg rkzwueuybj (fskqtbahwp, 54.0 - 91.0) View more | - | 01 Jul 2018 | |||
NCT01290471 (ASCO2013) Manual | Phase 1 | 15 | kahyjipvbp(mxxfzvgfae) = fatigue, anemia, and appetite loss, seen in 20, 13, and 7% of cases, respectively umznvygkbu (gpofmkrpwq ) | Positive | 20 May 2013 |